AbbVie, Teva Pay-For-Delay Deal Draws More Antitrust Claims

Law360, New York (May 8, 2013, 3:54 PM EDT) -- AbbVie Inc. and Teva Pharmaceutical Industries Ltd. were sued Tuesday in Pennsylvania federal court over a patent settlement that allegedly delayed market entry of a generic form of AbbVie's Niaspan cholesterol drug, the latest of several putative antitrust class actions against the companies.

A New York hotel workers union benefits plan lodged a proposed class action challenging a so-called pay-for-delay deal that resolved a patent dispute between two of the drug companies' predecessors. The suit — filed by named plaintiff New York Hotel Trades Council and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.